Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in adolescents with OAB urinary incontinence
NCT02097121Phase 3Terminated
- Sponsor
- Allergan
- Start
- May 2014
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of onabotulinumtoxinA in overactive bladder (OAB), sponsored by Allergan. Started May 2014; status: terminated.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02097121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097121.